IQVIA reported $16.6B of revenue over the trailing twelve months, +7.3% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $16.6B (to Q1 2026). Net income: $1.39B, trailing twelve months to Q1 2026. Free cash flow: $2.12B, trailing twelve months to Q1 2026. Operating margin: 13%, trailing twelve months to Q1 2026.

IQVIQVIA

Healthcare

$259.96+37% 1Y

$259.96

$156.6652 weeks$275.17

IQV as reported

IQVIA reported $16.6B of revenue over the trailing twelve months, +7.3% on the year before. 11 reported series are charted on this page, each one as filed.

$16.6B

Revenue, trailing twelve months · to Q1 2026 · +7.3% against the twelve months before

Net income: $1.39B
Net income · +3.8% year on year · trailing twelve months to Q1 2026
Free cash flow: $2.12B
Free cash flow · −2.2% year on year · trailing twelve months to Q1 2026
Operating margin: 13%
Operating margin · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for IQV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$16.6B	+7.3%	Q1 2026
Net income	$1.39B	+3.8%	Q1 2026
EPS	$8.06	+10.0%	Q1 2026
Gross margin	33%	n/a	Q1 2026
Operating margin	13%	n/a	Q1 2026
Net margin	8.3%	n/a	Q1 2026
ROE	21%	n/a	Q1 2026
ROA	4.5%	n/a	Q1 2026
ROIC	8.8%	n/a	Q1 2026
Free cash flow	$2.12B	−2.2%	Q1 2026
P/E	32.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.